Bausch + Lomb (BLCO) announced CE Mark approval for the LuxLife full range of vision intraocular lens. The preloaded IOL provides patients with natural, continuous vision, from distance to near.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch Health price target lowered to $8 from $9 at Raymond James
- Bausch + Lomb price target lowered to $15 from $20 at H.C. Wainwright
- Bausch + Lomb price target lowered to $12 from $15 at Wells Fargo
- Bausch + Lomb price target lowered to $11 from $17 at BofA
- Bausch + Lomb price target lowered to $13 from $14 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue